U.S. Markets open in 5 hrs 40 mins

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W
5.87+0.07 (+1.21%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close5.80
Open5.65
Bid0.00 x 800
Ask0.00 x 800
Day's Range5.51 - 5.87
52 Week Range5.16 - 10.34
Volume40,582
Avg. Volume79,698
Market Cap112.696M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02
    GlobeNewswire

    Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02

    New clinical data demonstrates antitumor effect of EVX-01 in combination with anti-PD1 treatmentObjective Response Rate (ORR) of 67% with EVX-01 + anti-PD1 treatment in nine metastatic melanoma patients, including 22% Complete Response (CR) and 44% Partial Response (PR)Clinical trial data supports the proprietary AI-Immunology platform, PIONEER, with regard to: neoepitope prediction, de novo T-cell activation and clinical response in cancer patients Phase 2 trial of EVX-01 in melanoma, planned t

  • Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8
    GlobeNewswire

    Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8

    COPENHAGEN, Denmark, July 07, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will hold a conference call to discuss Phase 1/2a data on EVX-01 and EVX-02 on Thursday, July 8, 2021. Lars Wegner, CEO of Evaxion, Glenn Vraniak, CFO, and Niels Iversen Moller, co-founder and CBO,

  • Evaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic Programming
    GlobeNewswire

    Evaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic Programming

    COPENHAGEN, Denmark, June 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the acceptance of a new scientific paper by the International Conference on Machine Learning (ICML 2021). A draft of the article is available on the open-access scientific server bioRxiv.org. The paper is entitled “Efficien